Every Form 4 that Adaptive Biotechnologies Corporation (ADPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADPT filings page.
Adaptive Biotechnologies Corp (ADPT) President and COO Julie Rubinstein exercised options for 11,881 shares at $12.14 per share on each of October 6, 7 and 8, 2026, and reported sales on each date. October 6 sale lots were 9,381 shares at a weighted-average $27.36, 1,100 at $28.21, 901 at $29.71 and 499 at $30.53 per share. She sold 11,881 shares at a weighted-average $26.40 on October 7 and 11,881 at $25.66 on October 8. The transactions were under a Rule 10b5-1 plan adopted November 18, 2025.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD Susan Bobulsky sold 6,444 shares of common stock at $30 per share on October 6, 2026. The sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025. She directly held 389,350 shares after the transaction.
Adaptive Biotechnologies Corp (ADPT) President and COO Julie Rubinstein exercised options covering 11,881 shares on each of October 1, 2 and 5, 2026, at an exercise price of $12.14 per share, and sold 35,643 shares over those dates. The sales comprised 6,081 shares at a weighted average price of $27.57 and 5,800 at $28.56 on October 1; 11,881 at $28.13 on October 2; and 6,699 at $28.82 and 5,182 at $29.67 on October 5. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted November 18, 2025; the options were fully vested and exercisable.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised three stock-option tranches on October 1, 2026, for 8,038 shares at an $8.46 exercise price, 9,377 shares at $3.99, and 9,377 shares at $8.12; corresponding common-stock acquisitions were reported. On the same date, Lo sold 8,094 shares at a weighted-average price of $27.52 and 18,698 shares at a weighted-average price of $28.61. Both sale prices were weighted averages within ranges stated in the transaction footnotes. The transactions were made under a Rule 10b5-1 trading plan adopted September 15, 2025.
Adaptive Biotechnologies Corp (ADPT) reported that Chief People Officer Francis Lo exercised employee stock options for 105,560 shares of common stock on September 16, 2026, at exercise prices between $3.99 and $12.14 per share, and on the same day sold 115,406 shares of common stock in market transactions.
The sales, made at weighted average prices of $28.02 and $28.57 per share within disclosed price ranges, were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025. An additional 2,500 shares are reported as indirectly held through Lo’s spouse.
Adaptive Biotechnologies Corp (ADPT) reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,195 shares of common stock on September 15, 2026, at a price of $27.00 per share in an open-market or private transaction. After this sale, she held 395,794 shares directly.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Susan Bobulsky on December 16, 2025.
Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a bona fide gift of 12,539 shares of common stock on August 31, 2026. The transaction was a disposition by gift, not a sale for value, and Owen now holds 66,100 shares of Adaptive Biotechnologies common stock directly.
Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a sale of company stock. On 2026-08-26, Owen sold 9,615 shares of Common Stock in a sale in open market or private transaction at $26.00 per share, and reported owning 78,639 shares of Common Stock directly after the transaction.
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg reported an option exercise and related share sales. On 2026-08-18, he exercised a stock option for 15,000 shares of common stock at an exercise price of $6.32 per share, fully using an option that would have expired on October 18, 2026. He then sold 30,664 shares of common stock in two transactions at weighted average prices of $24.39 and $24.41 per share, with actual sale prices ranging from $24.38–$24.44 as disclosed in the footnotes.
Adaptive Biotechnologies Corp (ADPT) reported insider transactions by CEO and Chairman Chad M. Robins involving an exercise-and-sell pattern over two days. On August 17 and 18, 2026, Robins exercised stock options for a total of 600,000 shares of common stock at an exercise price of $6.55 per share. He then sold 600,000 shares of common stock in multiple open-market transactions at weighted average prices around $24–$26 per share, as described in the price-range footnotes. The options exercised were fully vested and would have expired on February 7, 2028.
Adaptive Biotechnologies Corp (ADPT) director Peter M. Neupert reported an option exercise and significant share sales. He exercised 15,000 stock options for Common Stock at an exercise price of $6.32 per share, fully exhausting that option grant. On the same date, he sold an aggregate 124,690 shares of Common Stock in open-market transactions at weighted average prices around $25.10–$25.27 per share, as detailed in price-range footnotes.
Adaptive Biotechnologies Corp executive Susan Bobulsky, Chief Commercial Officer, MRD, reported selling 3,000 shares of common stock on August 10, 2026 at $25.00 per share in an open market or private transaction. Following this sale, she directly holds 396,989 shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 16, 2025.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,299 shares of Common Stock on July 30, 2026 at $24.00 per share in an open-market or private transaction. Following this sale, she directly holds 399,989 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was executed under a pre-arranged trading framework.
Adaptive Biotechnologies Corp chief scientific officer Harlan S. Robins exercised a fully vested stock option for 284,800 shares of common stock at $6.55 per share and sold 492,400 shares in two transactions at weighted-average prices of $21.72 and $22.12 on July 21, 2026.
All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 13, 2026.
Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 5,000 shares of Common Stock on July 16, 2026 at $23.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025, and she now directly holds 401,288 shares of Common Stock.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised employee stock options covering 105,762 common shares at exercise prices of $7.80, $8.46 and $12.14, and sold 105,762 shares of common stock at a weighted average price of $22.59 on July 15, 2026.
After these transactions, he directly held 230,713 common shares and indirectly held 2,500 shares through his spouse. All transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026. The sales occurred in two blocks at weighted-average prices of $21.74 and $22.45 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were scheduled in advance rather than timed discretionarily. After these sales, he continues to hold a significant direct equity position in the company.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and pre-planned share sales. On July 1–2, 2026, Lo exercised stock options covering 75,621 shares of common stock and sold 95,842 shares in open-market transactions at weighted average prices in the low $20s per share.
The filing states these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were pre-scheduled. After the transactions, Lo directly held 230,713 shares of common stock, plus 2,500 shares held indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 487 shares of common stock at $22.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and she continues to hold 406,288 shares directly after the sale.
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benzeno, reported a series of option exercises and related stock sales. She exercised options for 114,329 shares of common stock at strike prices between $3.99 and $12.14 per share.
On June 26 and 29, 2026, she sold a total of 165,802 shares in open-market transactions at weighted-average prices of $21.00 and $21.14 per share. After these transactions, she directly holds 221,278 shares of Adaptive Biotechnologies common stock.
The filing notes that all transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief Commercial Officer for MRD, Susan Bobulsky, reported an open-market sale of 5,000 shares of Common Stock at $20.50 per share. After this transaction, she directly holds 406,775 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was scheduled in advance.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an exercise-and-sale transaction in company stock. On June 25, 2026, she exercised stock options to acquire 52,084 shares of Common Stock at an exercise price of $7.80 per share, then sold 52,084 shares in an open-market transaction at a weighted-average price of $20.18 per share.
The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating they were scheduled in advance. Following the transactions, Griffin directly held 15,625 shares of Adaptive Biotechnologies Common Stock.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of company common stock. He sold 100,000 shares on June 15, 2026 at a weighted-average price of $17.37 per share and 6,160 shares on June 16, 2026 at a weighted-average price of $18.01 per share.
All transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After these sales, Robins directly holds 1,405,898 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 5,000 shares of common stock at $19.00 per share on June 11, 2026. After this transaction, she directly holds 411,775 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.
On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 11,000 shares of Common Stock at $18.00 per share. After the transaction, she directly holds 416,775 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel executed a small mandated share sale tied to equity compensation taxes. On May 18, 2026, he sold 3,115 shares of common stock at $13.04 per share to cover tax withholding obligations from vesting restricted stock units. The company’s equity incentive plan required this “sell to cover” transaction, and the footnote states it was not a discretionary trade. After the sale, Piskel directly held 256,725 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an option exercise and related share sale. On April 27, 2026, she completed an open-market sale of 19,037 shares of common stock at a weighted average price of $14.23 per share.
That same day, she exercised stock options to acquire 14,707 shares of common stock at an exercise price of $8.46 per share from a grant vesting over four years and expiring in 2033. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a mix of option exercises and share sales. Over April 22–24, 2026, she exercised stock options covering 44,166 shares of Common Stock at an exercise price of $8.46 per share and sold 57,180 shares in open-market transactions at weighted average prices around $14 per share, as detailed in price ranges in the footnotes. After these transactions, she directly holds 382,132 shares of Common Stock and 60,438 stock options. The filing notes that all transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of pre-planned stock transactions in common stock. Under a Rule 10b5-1 trading plan, she exercised stock options to acquire a total of 56,047 shares at exercise prices of $8.46 and $12.14 per share, then sold 69,061 shares in open‑market transactions at weighted average prices in the mid‑$14 range. Following these exercises and sales, she continues to hold a substantial direct ownership position in Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and share sales in Adaptive Biotechnologies Corp. Between April 14 and April 16, 2026, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $8.46 per share.
Over the same period, she sold 57,180 shares of common stock in open-market transactions, including sales reported at weighted average prices of $14.18, $14.61 and $14.56 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following the transactions, she directly holds 408,160 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales. She exercised options to acquire 44,166 shares of common stock at exercise prices of $7.27 and $8.46 per share, then sold 57,180 shares in open-market transactions at weighted average prices generally in the mid‑teens per share. These trades, executed on April 9, 10, and 13, were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly owned 421,174 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised stock options and sold shares in a planned transaction. On April 8, 2026, Lo exercised options to acquire 2,344 shares of common stock at $3.99 per share, then sold 22,564 shares of common stock in an open-market sale at a weighted average price of $15.07 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo owns 271,154 shares directly and an additional 2,500 shares indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported an open-market sale of 10,000 shares of common stock on April 8, 2026 at a weighted-average price of $14.85 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025. Following this transaction, Robins directly holds 1,512,058 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of company common stock executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 83,332 shares on April 6, 2026 at a weighted average price of $14.41 per share in multiple trades between $14.19 and $14.84. He then sold 37,263 shares on April 8, 2026 at a weighted average price of $15.19 per share, with individual trades between $15.00 and $15.53.
Across both transactions, Robins sold 120,595 shares and directly held 2,180,518 shares of Adaptive Biotechnologies common stock following the most recent sale.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades. She exercised stock options for 56,047 shares of common stock at exercise prices of $7.27 and $12.14 per share and sold 69,061 shares in open‑market transactions at weighted average prices ranging from about $13.39 to $15.48 between April 6 and April 8, 2026. After these transactions, she directly held 434,188 shares of common stock and retained vested stock options representing 37,553 shares. The filing notes that all transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025.
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions. She exercised options to acquire 29,444 shares of common stock at $7.27 per share, then sold 38,120 shares of common stock in open-market trades at weighted average prices of $14.45 and $14.60 per share.
All transactions were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating they were pre-scheduled. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related share sales in late March. She exercised stock options for 44,166 shares of common stock at an exercise price of $7.27 per share, then sold 57,180 shares of common stock in open-market transactions at prices in the $12–$13 range. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following the trades, she directly holds 455,878 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and related stock sales in common stock. Over March 24–26, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $7.27 per share. She then sold 57,180 shares in open-market transactions at weighted average prices ranging from $13.45 to $14.49 per share. Following these transactions, she directly holds 468,892 shares of Adaptive Biotechnologies common stock. The filing notes that all transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and share sales in March 2026. She exercised stock options to acquire a total of 44,166 shares of common stock at exercise prices of $6.55 and $7.27 per share, then sold 57,180 shares in open-market transactions.
The sales occurred in three equal blocks of 19,060 shares at weighted average prices of $13.18, $13.37 and $13.83 per share. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 481,906 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies President and COO Julie Rubinstein reported an exercise-and-sell transaction pattern in company stock. Over three days, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $6.55 per share.
She then sold 57,180 shares of common stock in open-market transactions at reported prices of $13.41, $13.40, and $13.18 per share, with each sale executed as multiple trades within disclosed price ranges. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Following these transactions, Rubinstein directly owned 494,920 shares of Adaptive Biotechnologies common stock, indicating she retained a substantial equity position after the option exercises and sales.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and stock sales. She exercised options to acquire 44,166 shares of common stock at an exercise price of $6.55 per share and sold 179,703 shares in multiple open-market transactions, including sales at $12.63, $12.96, $13.17, $13.43 and $14.08 per share. A portion of the shares sold was mandated to cover tax withholding on RSU vesting, and all transactions were carried out under a Rule 10b5-1 trading plan. After these transactions, she directly holds 507,934 shares of common stock and retains 62,827 fully vested stock options exercisable at $6.55 per share expiring on February 7, 2028.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an open-market sale of 15,394 shares of Common Stock at a weighted-average price of $13.91 per share. The shares were sold in multiple trades between $13.84 and $13.96. After this sale, she directly holds 15,625 shares, meaning her personal stake was significantly reduced but she continues to own stock in the company.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an open-market sale of 30,593 shares of common stock at a weighted average price of $14.08 per share on March 11, 2026. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance. Following the sale, Lo directly holds 291,374 shares of Adaptive Biotechnologies common stock and has an additional 2,500 shares held indirectly through a spouse. The sale price range for the trades was between $13.81 and $14.38 per share.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 41,338 shares of common stock on March 11, 2026 at an average price of $13.17 per share. According to the disclosure, this transaction was required to cover tax withholding obligations related to vesting restricted stock units and was executed under a mandatory “sell to cover” election, meaning it was not a discretionary trade. Following the sale, Bobulsky directly holds 427,775 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benz eno, reported an open-market sale of 63,103 shares of common stock at $13.17 per share. After the transaction, she directly holds 272,751 shares.
The company’s equity plan required this sale to cover tax withholding on vested restricted stock units, so it was a mandated “sell-to-cover” transaction rather than a discretionary trade.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported a mandated sale of 18,672 shares of Common Stock on March 11, 2026. The shares were sold at an average price of $13.17 per share and were executed as an open-market transaction.
According to the disclosure, this sale was required to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The footnote states the transaction was a “sell to cover” and not a discretionary trade by Piskel. After the sale, he directly holds 259,840 shares of Adaptive Biotechnologies Corp common stock.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported selling a total of 470,266 shares of common stock on March 11, 2026 at $13.17 per share. According to the footnotes, both sales were mandated "sell to cover" transactions to satisfy tax withholding on vesting RSUs and performance share units, and did not represent discretionary trading decisions. After these transactions, Robins directly owned 1,522,058 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported mandated share sales tied to equity award vesting. On March 11, 2026, he sold a total of 470,167 shares of Common Stock at $13.17 per share in open-market transactions.
Footnotes explain these sales were required to cover tax withholding obligations from vesting RSUs and performance share units under the company’s equity incentive plans, and they were not discretionary trades. After these transactions, Robins directly holds 2,301,113 shares of Adaptive Biotechnologies Common Stock.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an exercise-and-sell trading pattern in March 2026. She exercised stock options for a total of 68,328 shares of Common Stock at exercise prices of $6.55 and $12.14 per share, then sold 81,342 shares in open-market transactions.
The sales occurred on March 6, 9 and 10, 2026 at weighted-average prices including $15.14, $14.79 and $14.68 per share. All transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 643,471 shares of Common Stock.